Trump signs order to ensure 'resilient' supply chain for essential medicines in US
Active Pharmaceutical Ingredients
Reserve (SAPIR) with critical drug components, the White House said on Wednesday.
The Office of the Assistant Secretary for Preparedness and Response within the
Department of Health and Human Services
is tasked with developing a list of about 26 critical drugs vital to "national health and security", the White House said in a fact sheet.
Finance
Value and Valuation Masterclass - Batch 4
By CA Himanshu Jain
View Program
Artificial Intelligence
AI For Business Professionals Batch 2
By Ansh Mehra
View Program
Finance
Value and Valuation Masterclass - Batch 3
By CA Himanshu Jain
View Program
Artificial Intelligence
AI For Business Professionals
By Vaibhav Sisinity
View Program
Finance
Value and Valuation Masterclass - Batch 2
By CA Himanshu Jain
View Program
Finance
Value and Valuation Masterclass Batch-1
By CA Himanshu Jain
View Program
"The Order directs the Office ... and ready the SAPIR repository to receive and maintain the Active Pharmaceutical Ingredients (APIs) used to make these critical drugs."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
Eli Lilly to raise UK price of weight-loss drug Mounjaro by 170%
Eli Lilly will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, it said on Thursday, amid a White House push to get drugmakers to raise medicine prices in Europe to allow for price cuts in the United States. The new price, which also applies to Lilly's type 2 diabetes medicine that has the same name, is effective from September. The price for a month's supply of the highest dose of the medicine will increase from £122 to £330, Lilly said. The higher price will affect those who pay for Mounjaro privately, but will not affect those prescribed the medicine through the British public healthcare system, which has a separate deal, a Lilly spokesperson said. The U.S. drugmaker said that when it launched Mounjaro in Britain it agreed to a list price "significantly below" that in its three other European markets to prevent delays in availability through Britain's National Health Service (NHS). "We are now aligning the list price more consistently," Lilly said. The move reflects how the pharmaceutical industry is navigating policy changes in the United States, by far its most lucrative market, where President Donald Trump is pushing for lower domestic prices and encouraging price hikes overseas. Last week Eli Lilly CEO David Ricks told an investor call that parity between U.S. and European drug pricing was desirable in the long run, though he warned that European governments "are not signing up to pay more for drugs". The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. Trump says he wants to narrow this gap to stop Americans from being "ripped off." Reuters reported last week that the Trump administration has been talking to drugmakers about ways to level the playing field for medicine prices. A list price is set by the drug manufacturer before any rebates or discounts. Lilly said it was working with private UK healthcare providers, such as online pharmacies, who can set their own prices, to ensure continued access to the medicines. Lilly launched Mounjaro in the UK in February last year, while rival Novo Nordisk's Wegovy treatment has been available in the country since September 2023.
Time of India
2 days ago
- Time of India
Apollo Hospitals shares in focus as brokerages hike target prices post strong Q1FY26 results
Apollo Hospitals shares are likely to be in focus on Thursday, August 14, after the company posted a strong set of Q1FY26 results , prompting multiple brokerage firms to raise their target prices for the stock. The healthcare major reported a consolidated net profit of Rs 433 crore for the quarter ended June 30, 2025, marking a 42% year-on-year increase from Rs 305 crore in the same period last year. On a sequential basis, PAT was up 11% from Rs 390 crore in Q4FY25. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program Revenue from operations in Q1FY26 rose 15% year-on-year to Rs 5,842 crore compared to Rs 5,086 crore in Q1FY25. Sequentially, revenue grew 4.5% from Rs 5,592 crore in the March quarter. The robust performance was supported by growth across segments, improved specialty mix, and operational efficiency gains. Nuvama: Buy| Target price: Rs 9,010 Nuvama has raised its target price for Apollo Hospitals to Rs 9,010 from Rs 8,635, maintaining a 'Buy' rating. Live Events The brokerage noted strong performance from HealthCo and said sustained execution remains key. It expects hospital growth from H2FY26 through phased bed expansion, higher international patient inflows, and an improved specialty mix. Nuvama also highlighted potential value unlocking from the Keimed merger, front-end restructuring, and a possible listing within 18 months. HealthCo's valuation multiple was raised to 26x from 22x, and FY26E/FY27E EBITDA estimates were increased by 2% and 4%, respectively. Motilal Oswal: Buy| Target price: Rs 9,010 Motilal Oswal also raised its target price to Rs 9,010 from Rs 8,720 while maintaining a 'Buy' rating. The firm cited broad-based growth with EBITDA and PAT beating estimates on cost optimisation and noted that profitability was boosted by lower operating expenses. It highlighted a 14% year-on-year rise in surgical revenues on the back of strong CONGO therapy momentum. HealthCo is on track for cash EBITDA breakeven (excluding ESOP) by Q2FY26/Q3FY26. The brokerage expects 15%, 21%, and 28% CAGR in revenue, EBITDA, and PAT, respectively, over FY25–FY27 and has raised its FY26/FY27 earnings estimates by 7%. Avendus: Buy| Target price: Rs 8,765 Avendus has increased its target price for Apollo Hospitals to Rs 8,765 from Rs 8,515, reiterating a 'Buy' call. The brokerage has advanced the breakeven timeline for the online business EBITDA to FY27 from FY28 earlier. It projects ex-Keimed revenue CAGR at 17% in FY25–FY27, with EBITDA expected at Rs 510 crore and Rs 770 crore for FY26 and FY27, respectively. Offline pharmacy revenue CAGR is also projected at 17%, while existing units' EBITDA CAGR is estimated at 16% in the same period. Avendus factors in the AHCo–Keimed merger in April 2026 and the APL front-end acquisition in April 2027. It expects healthcare services EBITDA CAGR of 14% and AHLL at 22% over FY25–FY27. FY26/FY27 EBITDA estimates have been raised by 4% each, driven by higher AHCo EBITDA, partly offset by new hospital losses. Also read: Zerodha's Nithin Kamath on how a boring, invisible Sebi step brought windfall gains for retail investors ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
2 days ago
- Time of India
Dangerous virus on the prowl? Scientists investigate Colorado rabbits with tentacles after alarming mutation fears
Colorado wildlife officials are urging calm after a spate of unusual sightings, rabbits with dark, horn-like growths sprouting from their heads and faces, has stirred public unease and speculation online. While experts say the condition, known as cottontail rabbit papillomavirus (CRPV), is not currently transmissible to humans, some epidemiologists are warning that close monitoring is essential to guard against any future spillover. The disease, spread by biting insects such as mosquitoes and fleas, causes grotesque, wart-like tumors on infected rabbits. In recent days, residents across Northern Colorado have reported seeing the animals in alarming numbers, sometimes with growths obstructing their vision or mouths. Finance Value and Valuation Masterclass - Batch 4 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Finance Value and Valuation Masterclass - Batch 3 By CA Himanshu Jain View Program Artificial Intelligence AI For Business Professionals By Vaibhav Sisinity View Program Finance Value and Valuation Masterclass - Batch 2 By CA Himanshu Jain View Program Finance Value and Valuation Masterclass Batch-1 By CA Himanshu Jain View Program Although CRPV has been documented for decades and is considered largely benign in wild rabbit populations, veterinary virologists note that papillomaviruses have a history of evolving. In rare cases, similar animal viruses have jumped species barriers, raising questions about whether climate change, urban expansion, and surging insect populations could create conditions for mutation. Possible impacts on domestic animals The virus is more dangerous for domesticated rabbits, where it can cause malignant tumors. Pet owners are advised to keep rabbits indoors if infected wildlife are present nearby and to seek veterinary care immediately if symptoms appear. Live Events There is currently no vaccine or treatment for CRPV, either for wild or domestic rabbits. Colorado wildlife officials stress that the public should avoid touching, feeding, or attempting to capture the infected animals. For now, the official message remains clear to keep your distance, protect your pets, and let scientists do their work. FAQs What is the horned rabbit virus ? The horned rabbit virus, formally known as cottontail rabbit papillomavirus (CRPV), is a wildlife disease that causes wart-like or horn-like growths on rabbits' heads and faces. Can the horned rabbit virus infect humans? Currently, there is no evidence that CRPV can infect humans or most household pets. Scientists say it is species-specific, but they continue to monitor for potential mutations. How does the virus spread? CRPV spreads mainly through biting insects such as mosquitoes, fleas, and ticks, making infections more common in warmer months.
